In 2023, sales of Non-Steroidal Anti-inflammatory and Antirheumatic medicines in Canada stood at a certain level, and forecasts from 2024 to 2028 anticipate a gradual decline. From 2024's forecasted value of 240.7 million, year-on-year variations show a slight downward trend, approximately a 0.86% decrease annually. The five-year compound annual growth rate (CAGR) suggests a modest decline in sales, emphasizing a contraction in the market.

Future trends to watch for include:

Potential technological advancements in treatment alternatives that might affect market dynamics.
Influences from regulatory changes that could impact drug pricing and accessibility.
Increasing preference for personalized medicine affecting demand for traditional anti-inflammatory drugs.